
1. science. 2019 aug 30;365(6456). pii: eaau1682. doi: 10.1126/science.aau1682.

validation protein kinase pfclk3 multistage cross-species malarial
drug target.

alam mm(1), sanchez-azqueta a(2), janha o(2), flannery el(3), mahindra a(4),
mapesa k(4), char ab(5), sriranganadane d(6), brancucci nmb(7), antonova-koch
y(8), crouch k(1), simwela nv(1), millar sb(1), akinwale j(9), mitcheson d(10),
solyakov l(9), dudek k(9), jones c(9), zapatero c(11), doerig c(12), nwakanma
dc(13), vázquez mj(11), colmenarejo g(14), lafuente-monasterio mj(11), leon
ml(11), godoi phc(6), elkins jm(15), waters ap(1), jamieson ag(4), álvaro ef(11),
ranford-cartwright lc(5), marti m(1), winzeler ea(8), gamo fj(11), tobin ab(16).

author information: 
(1)wellcome centre integrative parasitology, university glasgow, glasgow
g12 8qq, uk.
(2)centre translational pharmacology, institute molecular cell systems
biology, university glasgow, glasgow g12 8qq, uk.
(3)novartis institute biomedical research, emeryville, ca 94608, usa.
(4)school chemistry, university glasgow, glasgow g12 8qq, uk.
(5)institute biodiversity, animal health comparative medicine, college 
medical, veterinary life science, university glasgow, glasgow g12 8qq, uk.
(6)structural genomics consortium, universidade estadual de campinas, campinas,
são paulo 13083-886, brazil.
(7)department medical parasitology infection biology, swiss tropical and
public health institute, 4051 basel, switzerland.
(8)skaggs school pharmaceutical sciences, uc health sciences center for
immunology, infection inflammation, university california, san diego,
school medicine, la jolla, ca 92093, usa.
(9)medical research council toxicology unit, university leicester, leicester
le1 9hn, uk.
(10)department molecular cell biology, university leicester, leicester le1 
9hn, uk.
(11)diseases developing world, glaxosmithkline, 28760 tres cantos, madrid,
spain.
(12)biomedical science cluster, school health biomedical sciences, royal
melbourne institute technology, melbourne, vic 3000, australia.
(13)mrc unit gambia, fajara, banjul, gambia.
(14)biostatistics bioinformatics unit, imdea food institute, 28049 madrid,
spain.
(15)structural genomics consortium, nuffield department clinical medicine,
university oxford, oxford ox3 7dq, uk.
(16)centre translational pharmacology, institute molecular cell and
systems biology, university glasgow, glasgow g12 8qq, uk.
andrew.tobin@glasgow.ac.uk.

comment in
    nat rev drug discov. 2019 oct;18(11):824.

the requirement next-generation antimalarials curative and
transmission-blocking necessitates identification previously undiscovered 
druggable molecular pathways. identified selective inhibitor the
plasmodium falciparum protein kinase pfclk3, used combination with
chemogenetics validate pfclk3 drug target acting multiple parasite
life stages. consistent role pfclk3 rna splicing, inhibition
resulted down-regulation 400 essential parasite genes.
inhibition pfclk3 mediated rapid killing asexual liver- blood-stage p. 
falciparum blockade gametocyte development, thereby preventing
transmission, also showed parasiticidal activity p. berghei p.
knowlesi hence, data establish pfclk3 target drugs, the
potential offer cure-to prophylactic transmission blocking in
malaria.

copyright © 2019 authors, rights reserved; exclusive licensee american
association advancement science. claim original u.s. government 
works.

doi: 10.1126/science.aau1682 
pmid: 31467193  [indexed medline]

